KPTI, US48576U2050

Investing.com lists USD 7.25 target for Karyopharm stock

Published on 10/20/2026 at 20:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 33.43 million versus USD 37.90 million on August 13, 2026. Karyopharm stock costs EUR 0.32 on October 20, 2026 at 7:53 p.m. CEST.

Analyst target and reporting date

Investing.com listed a USD 7.25 average 12-month target for Karyopharm on October 19, 2026.
Second-quarter 2026 revenue was USD 33.43 million versus USD 37.90 million a year earlier.
Karyopharm stock costs EUR 0.32 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.
Karyopharm is expected to report third-quarter 2026 results on November 2, 2026.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics (ISIN US48576U2050) has an average 12-month analyst target of USD 7.25, while the stock's Nasdaq quote was USD 0.36 on October 20, 2026. Investing.com listed four buy recommendations and a USD 7.25 average target on its Karyopharm page. The target is 95.03 percent above the USD 0.36 Nasdaq quote. Karyopharm stock was trading at EUR 0.32 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.

Revenue fell in the second quarter

Karyopharm reported USD 33.43 million of revenue for the second quarter of 2026, down from USD 37.90 million in the second quarter of 2025. The company also reported a USD 22.5 million operating loss for the quarter. These figures came with the company's August 13, 2026 results release, which also described progress toward a supplemental application for selinexor in myelofibrosis. Karyopharm Therapeutics published the results on that date.

Nasdaq quote stays near yearly low

The Nasdaq quote of USD 0.36 stood USD 0.05, or 16.13 percent, above the 52-week low of USD 0.31 on October 20, 2026. The 52-week high was USD 10.99, leaving the quote 96.72 percent below that level. Karyopharm's market capitalization was USD 8.1 million on October 20, 2026. The company's investor-relations page describes it as a commercial-stage pharmaceutical company and identifies Nasdaq ticker KPTI. Karyopharm Therapeutics says its lead product is XPOVIO, an oral exportin 1 inhibitor marketed in two U.S. oncology indications.

November 2 is the next date

MarketBeat estimates that Karyopharm will report third-quarter 2026 results on November 2, 2026, before the Nasdaq session opens. Its page gives a consensus revenue estimate of USD 33.54 million and expected earnings per share of minus USD 1.16. For comparison, Acrivon Therapeutics traded at USD 1.79 on Nasdaq on October 20, 2026, up 5.92 percent from USD 1.69, with a market capitalization of USD 76.9 million. Kura Oncology traded at USD 9.94 on Nasdaq, up 6.20 percent from USD 9.36, with a market capitalization of USD 884.3 million.

Target gap remains the key measure

The analyst target is far above the Nasdaq quote, while second-quarter revenue was lower than a year earlier. The November reporting date will provide the next company-specific test for revenue and earnings expectations.